Table 3. Estimated costs over 100 years at population level.
| Cost | Estimated cumulative costs over 100 years (THB) | ||
|---|---|---|---|
| No vaccination (screening only) | Routine 4vHPV vaccination | Routine and catch-up 4vHPV vaccination | |
| Direct medical costs of HPV-related diseases treatment | |||
| Cervical cancer | 77,212,923,754 | 52,312,413,664 | 47,143,360,147 |
| HPV16/18 CIN1 | 1,774,039,845 | 908,082,629 | 728,196,733 |
| CIN2/3 | 38,293,570,197 | 19,706,623,671 | 15,922,378,541 |
| HPV6/11 Genital warts | |||
| In male | 10,283,135,581 | 4,020,431,254 | 2,692,431,841 |
| In female | 9,986,580,109 | 3,366,656,208 | 1,864,840,212 |
| HPV6/11 related CIN1 | 396,580,852 | 160,732,517 | 107,751,083 |
| Total direct medical costs of HPV-related diseases treatment | 137,946,830,338 | 80,474,939,944 | 68,458,958,556 |
| HPV-related disease costs avoided* | 57,471,932,088 | 69,487,905,607 | |
| Vaccination cost | 0 | 17,108,393,827 | 24,943,313,705 |
* Net when compared to no vaccination.